Page 765 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 749

maturational characteristics, 165, 166, single nucleotide polymorphisms (SNPs), immune status, 5
166–169, 167t 655, 655b in ectious disease prevention, 3–5

mature orms, 168 Southern blot technique, 660–661, 662, 663 OSHA standards, 3
production, 164–165 targeted sequencing, 664 sa ety o cer, 3
specialized unctions, 180 molecular techniques, 654 statistical applications
granulocytic re erence range abnormalities, Hematology laboratory requency distribution, 19, 19t

173–174 control specimen, 13–15 histogram, 19
neutrophils unctions, 2 Westgard rules, 19–20, 20b
development, 165, 165 immune status techniques, 2
distribution, 165–166 hand hygiene, 6b Hematoma, 42, 520

granulation, 168–169 screening, 5 Hematopathology, 654
maturation, 165, 165 vaccination, 5 Hematopoiesis
maturational characteristics, 165, 166, vaccines, 5 blood cells examination
166–169, 167t in ection control cellular characteristics, 94, 96–97, 97t

mature orms, 168 decontamination, 8–10 cytoplasmic characteristics, 97–98
production, 164–165 hand antisepsis, 7b nuclear characteristics, 97
segmented orm, 168, 168 handwashing, 6–7, 7b blood cells origin
Granulocytes abnormalities OSHA medical waste standards, 11 blood cell development, 83, 85

cytoplasmic abnormality personal protective equipment (PPE), 7–8 mesoderm migration, 82
döhle bodies, 340t, 341, 342 pipetting sa eguards, 10 bone marrow
ehrlichia, 340t, 341–342, 342 policies and practices, 6 biopsy, 84
toxic granulation, 339t, 341, 341 processed specimens, 10 unction, 84–86

vacuoles, 340t, 342 processing protection, specimen, 10–11 growth actors and inhibitors, 89t
inherited unctional abnormalities sa ety manual, 6 microenvironment, 89t
Alder-Reilly inclusions, 340t, 343, 343 specimen-handling, 53 sites, 83–84
body uids, 344 standard precautions, 6 structure, 84–86

Chédiak-Higashi syndrome, 340t, 342–343, in ectious disease prevention cytokines
343 history, 3–4 colony-stimulating actors, 92
May-Hegglin anomaly, 340t, 342, 342 HIV and HBV, 3–5, 21 inter eron, 92, 93t
nuclear abnormality International Organization or Standardization interleukins (ILs), 93–94, 94, 718–720

hypersegmentation, 339, 339t, 341, 341 (ISO) 15189, 12 de nition, 82, 95
Pelger-Huët anomaly, 339t, 341, 341 quality assessment embryonic phase, 82
pyknotic nucleus, 339t, 341 bar code, 14 erythrocyte, 97, 98
Granulocytic kinetics, 165 components, 12 extramedullary, 83

Granulocytic (myeloid) series, 165 documentation, 14, 15 etal hepatic phase, 82–83
Granulomatous disease, chronic, 340t, 344 equipment maintenance, 14 growth actor
Granulopoiesis, 91 laboratory policies, 12 cellular sources, 92t, 720t
laboratory procedure manual, 13 characteristics, 92t

H methodology, 14 erythropoietin, 92t, 721t
Hageman actor, 529 patient identi cation, 13, 13b G-CSF, 721t
Hairy cell leukemia (HCL) quali ed personnel, 12 GM-CSF, 721t
clinical signs and symptoms, 422 regulations and organizations, 12 HPCs mobilization, 93

cytogenetics, 422 results, 15 IL-3, 721t
epidemiology, 422 specimen collection and storage, 13–14 M-CSF, 721t
laboratory ndings, 422, 423 specimen procurement and labeling, 13 human stem cells (HSC)
treatment and prognosis, 423 test requisition, 13 bone cells, 92

Hairy cell leukemia-variant (vHCL), 423 quality control (QC) erythropoiesis, 91
Ham method, acidi ed serum lysis test, 506, 680 accuracy, 15, 16 granulopoiesis, 91
Haptoglobin, 132 arithmetic mean, 16 lymphopoiesis, 91
Hazard Communication Standard (HCS), 3 calibration, 15 macrophages, 91–92

HBV (see Hepatitis B virus) changes, classi cation o , 18, 19 marrow stromal cells, 91
HCL (see Hairy cell leukemia) coe cient o variation (CV), 17–18 mast cells, 91
Heinz bodies, 114, 129, 150, 151, 328 computed-based, 18–19 megakaryopoiesis, 91
HELLP syndrome, 518 con dence, 18 progenitor blood cells, 90–91

Helmet cells, 146, 147 control specimens, 15 immunocompetent, 86
Hematocrit (Hct), 211 dispersion, 18 mature blood cells, 98
Hematological malignancy, 636–637, 636t documentation, 15 neutrophil, 97
Hematology, 156–157 dri , 18 ontogeny o

molecular genetics requency distribution, 19 early medullary hematopoiesis, 83
allele-speci c oligonucleotide PCR (ASO- histogram, 19 embryonic phase, 82
PCR), 657 Levey-Jennings chart, 18, 18 etal hepatic phase, 82–83
amplicons and amplicon control measures, mean, 16 overview o , 94

655 median, 16 primitive, 82
ampli cation products analysis, 657–660, mode, 16 secondary lymphoid tissues
658, 659, 660b precision, 16, 16 blood, 88
consensus primer PCR, 657 pro ciency testing, 16 lymph nodes, 88

loop-mediated isothermal ampli cation purpose, 15 spleen, 87, 87–88
(LAMP), 657 quantitative data analysis, 16 thymus, 86, 86–87
microarray gene chip technology, 665, 666 standard deviation (SD), 17 transcription actors, 93
nested primers, 656–657 standards, 16 Hematopoietic progenitor cells (HPCs), 90–91

next-generation sequencing, 661–664, 663, trend, 18 Heme biosynthetic pathway, 125, 127, 127
664 variance, 17 Heme pigment, 105
polymerase chain reaction, 655–656, 655b, variation measurement, 16–18 Heme/porphyrin synthesis, 271–272
656, 657t Westgard rules, 19–20, 20b Hemoglobin

quantitative PCR (Q-PCR), 657 sa ety 2,3-diphosphoglycerate role, 120
real-time PCR (R -PCR), 657 agencies and organizations, 2b abnormal molecules, 129–130